Format

Send to

Choose Destination
Antimicrob Agents Chemother. 2015 Mar;59(3):1802-5. doi: 10.1128/AAC.04809-14. Epub 2014 Dec 22.

Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City.

Author information

1
Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA.
2
The Dr. James J. Rahal Jr. Division of Infectious Diseases, New York Hospital Queens, Flushing, New York, USA.
3
Division of Infectious Diseases, SUNY Downstate Medical Center, Brooklyn, New York, USA jquale@downstate.edu.

Abstract

Eravacycline demonstrated in vitro activity against a contemporary collection of more than 4,000 Gram-negative pathogens from New York City hospitals, with MIC50/MIC90 values, respectively, for Escherichia coli of 0.12/0.5 μg/ml, Klebsiella pneumoniae of 0.25/1 μg/ml, Enterobacter aerogenes of 0.25/1 μg/ml, Enterobacter cloacae 0.5/1 μg/ml, and Acinetobacter baumannii of 0.5/1 μg/ml. Activity was retained against multidrug-resistant isolates, including those expressing KPC and OXA carbapenemases. For A. baumannii, eravacycline MICs correlated with increased expression of the adeB gene.

PMID:
25534744
PMCID:
PMC4325809
DOI:
10.1128/AAC.04809-14
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center